Snapshot from Jun 10, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / Zealand Pharma Presents Petrelintide Data
Tech data presentation

Zealand Pharma Presents Petrelintide Data

Analysis based on 6 articles · First reported May 27, 2026 · Last updated May 27, 2026

Sentiment
20
Attention
4
Articles
6
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The presentation of Phase 2 data for petrelintide by Zealand Pharma at a major scientific conference could positively impact Zealand Pharma's stock price if the results are favorable, signaling progress in its obesity pipeline. This event also highlights the ongoing collaboration with Roche, which could have broader implications for the pharmaceutical market.

Biotechnology Pharmaceuticals
Event Summary

Zealand Pharma announced it will present late-breaking Phase 2 ZUPREME-1 data on its amylin analog, petrelintide, at the American Diabetes Association's 2026 Scientific Sessions in New Orleans from June 5-8, 2026. The ZUPREME-1 trial, conducted across the United States, Poland, and Romania, evaluated petrelintide for the treatment of obesity and overweight with weight-related comorbidities. The data, developed in collaboration with Roche, has been selected for the ADA Official Press Program, indicating its significance in the metabolic health field. Presentations will include an ePoster Theater presentation and poster sessions by W. Timothy Garvey, Tim Heise, and Anna Katrina Jógvansdóttir Gradel.

Key Actions
100 Zealand Pharma announced data presentation
80 Zealand Pharma developed petrelintide Roche
70 American Diabetes Association selected ZUPREME-1 data Zealand Pharma
Entities Involved
stock
Zealand Pharma
Zealand Pharma is presenting Phase 2 ZUPREME-1 data on petrelintide, a key drug candidate in its obesity and metabolic health pipeline, at a significant scientific conference. This presentation could enhance its reputation and potentially its stock value if the data is well-received.
Importance 100 Sentiment 30
ngo
American Diabetes Association
The American Diabetes Association is hosting the Scientific Sessions where Zealand Pharma will present its data, providing a platform for scientific exchange in metabolic health.
Importance 60 Sentiment 0
per
David Kendall
David Kendall, Chief Medical Officer of Zealand Pharma, is quoted expressing enthusiasm for sharing the data at the American Diabetes Association's Scientific Sessions.
Importance 40 Sentiment 0
stock
Roche
Roche is collaborating with Zealand Pharma on the development of petrelintide, indicating a shared interest in the drug's progress.
Importance 30 Sentiment 10
per
W. Timothy Garvey
W. Timothy Garvey is a presenter for the petrelintide data at the American Diabetes Association's Scientific Sessions and will moderate a symposium.
Importance 20 Sentiment 0
per
Tim Heise
Tim Heise is a presenter for one of the petrelintide poster details at the American Diabetes Association's Scientific Sessions.
Importance 10 Sentiment 0
per
Anna Katrina Jógvansdóttir Gradel
Anna Katrina Jógvansdóttir Gradel is a presenter for one of the petrelintide poster details at the American Diabetes Association's Scientific Sessions.
Importance 10 Sentiment 0
cnt
United States
The United States is one of the countries where the ZUPREME-1 trial was conducted and where the American Diabetes Association's Scientific Sessions are taking place.
Importance 10 Sentiment 0
cnt
Poland
Poland is one of the countries where the ZUPREME-1 trial was conducted.
Importance 5 Sentiment 0
cnt
Romania
Romania is one of the countries where the ZUPREME-1 trial was conducted.
Importance 5 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.